Bristol-Myers Squibb (BMY) has started a new initiative with Tempus AI (TEM) to use artificial intelligence, multimodal real-world data, and data science techniques across five initial clinical trial programs, Tempus said Thursday.
The initiative will aim to optimize clinical trial designs and boost the success probability of key assets in solid tumor oncology, including lung, colon, and prostate cancers for the pharmaceutical company, Tempus said.
Financial terms of the initiative were not provided.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.
Comments